Compare Fastly Inc (FSLY) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fastly Inc vs Spyre Therapeutics Inc. Common Stock — how do they compare? Fastly Inc trades at $24.6 (market cap $4.32B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Spyre Therapeutics Inc. Common Stock is the larger of the two by market cap, and Fastly Inc is more actively traded (5,665,889 versus 1,441,031). Which is the better fit depends on your goals — on Pluang, investors hold Fastly Inc for 26 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| FSLY | SYRE | |
|---|---|---|
Market Cap | $4.32B | $7.52B |
Volume | 5,665,889 | 1,441,031 |
Sector | Technology | Health |
52-Week High | $33.50 | $108.92 |
52-Week Low | $7.86 | $22.18 |
Typical Hold Time | 26 Days | 0 Days |
Enterprise Value | $4.38B | $6.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Fastly (FSLY) trades at $25.00, down 5.41% over the past day, with a bullish technical signal from moving averages and support at $25. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $0.15 exceeding expectations, while revenue growth is robust at 23% year-over-year. However, net income remains negative, and cash flow trends show volatility, with a net outflow of $105.61 million in 2025. Recent news highlights insider selling by the CTO but also positive coverage of AI-driven growth potential.
The outlook for FSLY is mixed, with opportunities from AI infrastructure demand and revenue targets up to $1.3 billion by 2029, but risks include persistent losses, high valuation multiples, and competitive pressures. Analyst consensus is a 'Hold' with a $28.33 price target, suggesting limited near-term upside from current levels amid execution challenges.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Fastly Inc
Fastly operates a content delivery network, which is necessary for entities to provide faster and more reliable online content. Fastly's strategy differs from traditional CDNs, which focused on locating servers in as many locations as possible to store copies of files that consumers most use. Fastly has far fewer sites than traditional CDNs, but it houses servers in the most network-dense data centers. Instead of simply storing static content, it allows its customers to program on its platform, enabling edge computing and better service of the more dynamic content that was traditionally not well served by CDNs. Fastly gears its service to the largest, most sophisticated enterprises rather than small companies and generated about two thirds of its revenue in the United States in 2020.
Read more on FSLY →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
